Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,053.34 +34.95 (+0.70%) Dow
38,146.77 +243.48 (+0.64%) Nasdaq
15,791.66 +186.18 (+1.19%) Bitcoin USD
59,101.48 +1,948.38 (+3.41%) CMC Crypto 200
1,274.62 +3.88 (+0.31%)
argenx SE (ARGX)
| Previous close | 383.34 |
| Open | 387.38 |
| Bid | 390.09 x 100 |
| Ask | 391.25 x 100 |
| Day's range | 384.29 - 391.43 |
| 52-week range | 327.73 - 550.76 |
| Volume | |
| Avg. volume | 271,350 |
| Market cap | 23.249B |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2024 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/in
- GlobeNewswire
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART® treatment April 16, 2024 – 7:00am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that data from its Phase 3 ADHERE tri
- GlobeNewswire
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to continue the development of efgartigimod to Phase 3 in adults with primary Sjogren’s disease (SjD)
